Marston discusses his sub analysis of the VESALIUS-CV trial, which indicated reduced MACE risk in patients with diabetes and no atherosclerosis after evolocumab treatment.
Nicholas Marston, MD, MPH
Advertisement
Nicholas Marston, MD, MPH, is a cardiologist and an assistant professor of medicine at Brigham and Women's Hospital.
Articles by Nicholas Marston, MD, MPH
Marston discusses the CORE and CORE2 trials, highlighting olezarsen’s success in lowering fasting triglyceride.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Interstitial Lung Abnormalities: Recognition, Risk Stratification, and When to Act
2
Management Strategies for Hypercortisolism
3
Q&A: Intensive LDL Lowering and Cardiovascular Prevention Strategies, With Lawrence Leiter, MD
4
Long-Term Treatment Adherence and Persistence in Hypercortisolism
5